Maureen E. Mork

The University of Texas MD Anderson Cancer Center — United States

Medicine · Health Sciences

17h-index1.1kcitations88works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Genetic factors in colorectal cancer(53), Cancer Genomics and Diagnostics(29), Pancreatic and Hepatic Oncology Research(17), Colorectal Cancer Screening and Detection(16), Neuroendocrine Tumor Research Advances(13)

Publications88 total

Genotype-Phenotype Characterization of Lynch Syndrome–associated Upper Tract Urothelial Carcinoma
European Urology Oncology·2025· 1 cited
Empowering young-onset colorectal cancer patients with an accessible, self-navigable online platform for universal germline testing.
Journal of Clinical Oncology·2025
Prevalence of extracolonic malignancies in patients with familial adenomatous polyposis.
Journal of Clinical Oncology·2025
Gastric cancer prevention and screening during pancreatic cancer screening in high-risk individuals: an opportunity not to be missed
Gastrointestinal Endoscopy·2024
Data from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors
2024Open Access
Supplementary Table 2 from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors
2024Open Access
Supplementary Table 1 from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors
2024Open Access
Supplementary Figure 1 from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors
2024Open Access
Supplementary Table 3 from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors
2024Open Access
Supplementary Table 3 from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors
2024Open Access
Supplementary Figure 1 from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors
2024Open Access
Supplementary Table 1 from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors
2024Open Access
Supplementary Table 2 from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors
2024Open Access
Data from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors
2024Open Access
Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors
Cancer Prevention Research·2024· 7 cited
New-onset diabetes is a predictive risk factor for pancreatic lesions in high-risk individuals: An observational cohort study
Endoscopic Ultrasound·2024· 2 citedOpen Access
Germline testing identifies pathogenic/likely pathogenic variants in patients with pancreatic neuroendocrine tumors
Endocrine Abstracts·2023· 1 cited
Prevalence of germline variants in patients with pancreatic neuroendocrine tumors.
Journal of Clinical Oncology·2023· 1 cited
Colorectal surveillance outcomes from an institutional longitudinal cohort of lynch syndrome carriers
Frontiers in Oncology·2023· 9 citedOpen Access
Figure S2 from <i>In Silico</i> Systems Biology Analysis of Variants of Uncertain Significance in Lynch Syndrome Supports the Prioritization of Functional Molecular Validation
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Eduardo Vilar(22), Patrick M. Lynch(20), Sarah A. Bannon(18), Y. Nancy You(16), Miguel A. Rodrı́guez-Bigas(15), Florencia McAllister(14), Melissa W. Taggart(13), Ester Borràs(12), Kyle Chang(8), Amanda Cuddy(7), Anirban Maitra(7), Matthew H. G. Katz(7), Chirayu Mohindroo(7), Seyda Baydogan(7), Alison P. Klein(7), Surena F. Matin(6), Ana De Jesus‐Acosta(5), Parul Agarwal(5), Arvind Dasari(5), Michael P. Kim(5)